SUPPLEMENTARY MATERIALS

Contents

S.1. Literature Search	3
The Keywords	3
The Search Results	3
Table S1. Results of systematic searches.	3
S.2. Assessment of Quality of Study	4
Table S2. The assessment of quality of study for cohort studies using Newcastle-Ottawa Scale (NOS)	4
Table S3. The assessment of quality of study for case-control studies using Newcastle- Ottawa Scale (NOS)	5
S.3. Summary of outcomes for full dose	7
Table S4. Summary of outcomes for full dose	7
S.4. Summary of outcomes for booster dose 1	1
Table S5. Summary of outcomes for booster dose1	1
S.5. Summary of outcomes for booster vs full dose of the within 3 months or more model . 1	4
Table S6. Summary of outcomes for booster vs full dose of the within 3 months or moremodel1	4
S.6. Summary of outcomes for booster vs full dose of the within 3 months model 1	6
Table S7. Summary of outcomes for booster vs full dose of the within 3 months model 1	6
S.8. Detailed Results of VE Estimates and VE Reduction of Full Dose 1	8
Table S9. Detailed results of VE estimates and VE reduction of full dose for any infection outcome 1	8
Table S10. Detailed results of VE estimates and VE reduction of full dose for severe infection outcome 2	28
Table S11. Detailed results of VE estimates and VE reduction of full dose for symptomatic infection outcome 3	с 54
S.9. Detailed Results of VE Estimates and VE Reduction of Booster Dose	.3
Table S12. Detailed results of VE estimates and VE reduction of booster dose for any infection outcome 4	-3
Table S13. Detailed results of VE estimates and VE reduction of booster dose for severe infection outcome 5	51
Table S14. Detailed results of VE estimates and VE reduction of booster dose for symptomatic infection outcome 5	6
S.10. Detailed Results of Meta-analyses for the 'Within 3 Months' Model	3
Table S15. Detailed Results of meta-analyses for within 3 months model	3

S.11. Detailed Results of Meta-analyses for the 'Within 3 Months or More' Model 65
Table S16. Detailed Results of meta-analyses for within 3 months or more model
S.12. Sensitivity Analyses for the 'Within 3 Months' Model
Figure S1. The result of leave-one-out sensitivity analyses for any infection endpoint in the within 3 months' model
Figure S2. The result of leave-one-out sensitivity analyses for severe infection endpoint in the 'within 3 months' model
Figure S3. The result of leave-one-out sensitivity analyses for symptomatic infection endpoint in the 'within 3 months' model
S.13. Sensitivity Analyses for the 'Within 3 Months or More' Model
Figure S4. The result of leave-one-out sensitivity analyses for any infection endpoint in the 'within 3 months or more' model
Figure S5. The result of leave-one-out sensitivity analyses for severe infection endpoint in the 'within 3 months or more' model71
Figure S6. The result of leave-one-out sensitivity analyses for symptomatic infection endpoint in the 'within 3 months or more' model72

S.1. Literature Search

The Keywords

#1 (SARS-CoV-2) OR (COVID-19)

- #2 (Omicron) OR (B.1.1.529)
- #3 (Vaccine) OR (Vaccination)
- #4 (Vaccine efficacy) OR (Vaccine effectiveness)

The Search Results

Table S1. Results of systematic searches.

Database	Keywords	Search Result	Search-time
PubMed	#1 AND #2 AND #3 AND #4	121	April 6 th , 2022
ScienceDirect	#1 AND #2 AND #3 AND #4	475	April 6 th , 2022
CENTRAL	#1 AND #2 AND #3 AND #4	2	April 6 th , 2022
Web of Science	#1 AND #2 AND #3 AND #4	61	April 6 th , 2022
Scopus	#1 AND #2 AND #3 AND #4	619	April 6 th , 2022
medRxiv	#1 AND #2 AND #3 AND #4	455	April 6 th , 2022
bioRxiv	#1 AND #2 AND #3 AND #4	312	April 6 th , 2022
Bibliographic search	-	19	April 6 th , 2022

S.2. Assessment of Quality of Study

Table S2. The assessment of quality of study for cohort studies using Newcastle-Ottawa Scale (NOS)

NOS of Cohort Study										
Components	Hansen et al. (2021)	Abu-Raddad et al. (2022)	Monge et al., (2022)	Šmíd et al. (2022)	Fowlkes et al. (2022)					
	S	election								
Representativeness of the exposed cohort	*	*	*	*	*					
Selection of the non-exposed cohort	*	*	*	*	*					
Ascertainment of exposure	*	*	*	*	*					
Demonstration that outcome of interest was not present at start of the study	*	*	-	-	-					
	Con	ıparability								
Comparability of cohorts on the basis of design or analysis	*	**	*	*	*					
	E	xposure								
Assessment of outcome	*	*	*	*	*					
Enough follow-up time length for outcome to occur	*	*	*	*	*					
Adequacy of follow-up of cohorts	*	*	*	*	*					
Study Quality										
Total Score	8	9	7	7	7					
Interpretation	Good	Good	Good	Good	Good					

NOS of Case-Control Study										
	Selection				Comparability		Exposure		Study Quality	
Components	Is the case definition adequate?	Representative- ness of the cases	Selection of controls	Definition of controls	Comparability of cases and controls on the basis of the design or analysis	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non- response rate	Total Score	Interpretation
Buchan et al. (2021)	*	*	*	*	*	-	*	*	7	Good
Gray et al. (2021)	*	*	*	*	*	*	*	*	8	Good
Accorsi et al. (2022)	*	*	*	*	*	-	*	*	7	Good
Andrews et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Chemaitelly et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Collie et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Ferdinand et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Klein et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Lauring et al. (2022)	*	*	*	*	**	*	*	*	9	Good
Natarajan et al. (2022)	*	*	*	*	**	*	*	*	9	Good
Tartof et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Tenforde et al. (2022)	*	*	*	*	*	-	*	*	7	Good

Table S3. The assessment of quality of study for case-control studies using Newcastle-Ottawa Scale (NOS)

Thompson et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Tseng et al. (2022)	*	*	*	*	**	*	*	*	9	Good
Young-Xu et al. (2022)	*	*	*	*	*	*	*	*	8	Good
Zambrano et al. (2022)	*	*	*	*	*	*	*	*	8	Good

S.3. Summary of outcomes for full dose

Table S4. Summary of outcomes for full dose

Study	Endpoints	Vaccine	Study Design	Days Latitude	Follow-up Interval	SE	VE (95%CI)
Ferdinand et al., 2022	Severe	Mixture of mRNA	Case-control	60	0 to 2 months	8.163	71% (51% to 83%)
	infection	Mixture of mRNA	Case-control	180	2 to 3 months	5.357	65% (53% to 74%)
		Mixture of mRNA	Case-control	240	3 to 4 months	8.418	58% (38% to 71%)
		Mixture of mRNA	Case-control	300	5+ months	2.806	54% (48% to 59%)
	Symptomatic	Mixture of mRNA	Case-control	60	0 to 2 months	3.316	69% (62% to 75%)
	Infection	Mixture of mRNA	Case-control	180	2 to 3 months	2.551	50% (45% to 55%)
		Mixture of mRNA	Case-control	240	3 to 4 months	3.316	48% (41% to 54%)
		Mixture of mRNA	Case-control	300	5+ months	1.531	37% (34% to 40%)
Klein et al., 2022	Symptomatic	BNT162b2	Case-control	149	14 to 149 days	11.480	34% (8% to 53%)
	infection (Age 16- 17 years)	BNT162b2	Case-control	299	150+ days	12.245	-3% (-30% to 18%)
		BNT162b2	Case-control	149	14 to 149 days	6.888	45% (30% to 57%)
		BNT162b2	Case-control	299	150+ days	10.714	-2% (-25% to 17%)
		BNT162b2	Case-control	67	14 to 67 days	8.929	51% (30% to 65%)
Natarajan et al., 2022	Severe	AD26.COV2S	Case-control	120	7 to 120 days	6.378	67% (52% to 77%)
	infection	Mixture of mRNA	Case-control	120	7 to 120 days	3.571	78% (70% to 84%)
	Symptomatic	AD26.COV2S	Case-control	120	7 to 120 days	5.102	54% (43% to 63%)
	Infection	Mixture of mRNA	Case-control	120	7 to 120 days	2.041	79% (74% to 82%)
Tenforde et al., 2022	Severe infection	Mixture of mRNA	Case-control	256	256 days (median)	5.357	79% (66% to 87%)
Zambrano et al., 2022	Severe Infection	BNT162b2	Case-control	63	63 days (median)	5.357	90% (75% to 96%)
Accorsi et al., 2022*	Symptomatic	BNT162b2	Case-control	240	14+ days	2.653	0% (-5% to 5%)
	Infection	mRNA-1273	Case-control	240	14+ days	2.679	13% (7% to 18%)
Andrews et al., 2022	Symptomatic Infection	ChAdOx1 nCov-19	Case-control	28	2 to 4 weeks	4.566	49% (39% to 57%)

		ChAdOx1 nCov-19	Case-control	70	5 to 9 weeks	4.209	34% (25% to 42%)
		ChAdOx1 nCov-19	Case-control	105	10 to 14 weeks	3.750	29% (21% to 36%)
		ChAdOx1 nCov-19	Case-control	140	15 to 19 weeks	2.168	18% (13% to 22%)
		ChAdOx1 nCov-19	Case-control	175	20 to 24 weeks	1.071	4% (2% to 6%)
		ChAdOx1 nCov-19	Case-control	210	25+ weeks	0.765	-3% (-4% to -1%)
		BNT162b2	Case-control	28	2 to 4 weeks	0.791	66% (64% to 67%)
		BNT162b2	Case-control	70	5 to 9 weeks	0.791	49% (47% to 50%)
		BNT162b2	Case-control	105	10 to 14 weeks	0.714	30% (29% to 32%)
		BNT162b2	Case-control	140	15 to 19 weeks	0.612	15% (14% to 17%)
		BNT162b2	Case-control	175	20 to 24 weeks	0.714	12% (10% to 13%)
		BNT162b2	Case-control	210	25+ weeks	0.893	9% (7% to 11%)
		mRNA-1273	Case-control	28	2 to 4 weeks	2.015	75% (71% to 79%)
		mRNA-1273	Case-control	70	5 to 9 weeks	2.270	53% (48% to 57%)
		mRNA-1273	Case-control	105	10 to 14 weeks	1.454	36% (33% to 38%)
		mRNA-1273	Case-control	140	15 to 19 weeks	1.071	25% (23% to 27%)
		mRNA-1273	Case-control	175	20 to 24 weeks	1.684	15% (12% to 18%)
		mRNA-1273	Case-control	210	25+ weeks	5.306	15% (4% to 25%)
Buchan et al., 2021	Symptomatic	Mixture of mRNA	Case-control	59	7 to 59 days	5.357	36% (24% to 45%)
	Infection	Mixture of mRNA	Case-control	119	60 to 119 days	4.592	12% (3% to 21%)
		Mixture of mRNA	Case-control	179	120 to 179 days	3.571	15% (8% to 22%)
		Mixture of mRNA	Case-control	239	180 to 239 days	4.592	1% (-8% to 10%)
		Mixture of mRNA	Case-control	299	240+ days	8.673	2% (-17% to 17%)
		Mixture of mRNA	Case-control	59	7 to 59 days	50.000	55% (-106% to 90%)
		Mixture of mRNA	Case-control	119	60 to 119 days	37.755	37% (-71% to 77%)
		Mixture of mRNA	Case-control	179	120 to 179 days	9.184	75% (51% to 87%)
		Mixture of mRNA	Case-control	239	180 to 239 days	7.398	82% (62% to 91%)

		Mixture of mRNA	Case-control	299	240+ days	28.061	86% (-12% to 98%)
Chemaitelly et al.,	Symptomatic	BNT162b2	Case-control	30	0 to 1 month	5.408	62% (50% to 71%)
2022	Infection	BNT162b2	Case-control	60	1 to 2 months	5.612	46% (34% to 56%)
		BNT162b2	Case-control	90	2 to 3 months	5.281	36% (25% to 46%)
		BNT162b2	Case-control	120	3 to 4 months	5.051	29% (18% to 38%)
		BNT162b2	Case-control	150	4 to 5 months	6.173	11% (-2% to 22%)
		BNT162b2	Case-control	180	5 to 6 months	3.980	14% (6% to 22%)
		BNT162b2	Case-control	210	6 to 7 months	3.546	10% (2% to 16%)
		BNT162b2	Case-control	240	7 to 8 months	3.852	-8% (-15% to 0%)
		BNT162b2	Case-control	270	8 to 9 months	3.801	2% (-6% to 9%)
		BNT162b2	Case-control	300	9 to 10 months	3.903	-18% (-26% to -10%)
		BNT162b2	Case-control	330	10 to 11 months	4.796	0% (-10% to 9%)
		BNT162b2	Case-control	360	11+ months	6.378	17% (3% to 28%)
		mRNA-1273	Case-control	120	1 to 3 months	12.194	45% (16% to 64%)
		mRNA-1273	Case-control	180	4 to 6 months	3.495	21% (14% to 27%)
		mRNA-1273	Case-control	240	7+ months	3.444	-9% (-16% to -3%)
Collie et al., 2022	Severe Infection	BNT162b2	Case-control	NR	14+ days	6.888	50% (35% to 62%)
	Symptomatic Infection	BNT162b2	Case-control	NR	0+ days	4.847	70% (59% to 78%)
Lauring et al., 2022	Severe	Mixture of mRNA	Case-control	NR	7+ days	7.143	66% (49% to 77%)
Tartof et al., 2022	Infection	BNT162b2	Case-control	90	0 to 3 months	10.969	70% (41% to 84%)
		BNT162b2	Case-control	180	3 to 6 months	9.184	67% (44% to 80%)
		BNT162b2	Case-control	270	6+ months	5.102	68% (56% to 76%)
	Symptomatic	BNT162b2	Case-control	90	0 to 3 months	7.398	60% (43% to 72%)
	Infection	BNT162b2	Case-control	180	3 to 6 months	7.653	38% (21% to 51%)
		BNT162b2	Case-control	270	6+ months	4.592	41% (32% to 50%)
Thompson et al., 2022	Positive	Mixture of mRNA	Case-control	180	0 to 180 days	3.061	52% (46% to 58%)
	Covid-19	Mixture of mRNA	Case-control	360	180+ days	2.806	38% (32% to 43%)
		Mixture of mRNA	Case-control	179	0 to 179 days	6.378	81% (65% to 90%)

	Severe Infection	Mixture of mRNA	Case-control	359	180+ days	7.908	57% (39% to 70%)
Tseng et al., 2022	Positive	mRNA-1273	Case-control	90	14 to 90 days	4.209	44% (35% to 52%)
	Covid-19	mRNA-1273	Case-control	180	91 to 180 days	3.469	24% (16% to 30%)
		mRNA-1273	Case-control	270	181 to 270 days	1.811	14% (10% to 17%)
		mRNA-1273	Case-control	360	270+ days	2.704	6% (0% to 11%)
	Severe Infection	mRNA-1273	Case-control	NR	14+ days	18.852	85% (23% to 97%)
Yong-Xu, 2022	Positive Covid-19	Mixture of mRNA	Case-control	NR	NR	2.551	25% (20% to 30%)
Fowlkes et al., 2022	Positive	BNT162b2	Cohort	82	14 to 82 days	9.949	31% (9% to 48%)
	Covid-19	BNT162b2	Cohort	149	14 to 149 days	14.541	59% (22% to 79%)
		BNT162b2	Cohort	299	150+ days	29.847	62% (-28% to 89%)
Hansen et al., 2021	Positive Covid-19	BNT162b2	Cohort	30	27 to 28 days	12.806	55% (24% to 74%)
		BNT162b2	Cohort	60	31 to 60 days	15.944	16% (-21% to 42%)
		BNT162b2	Cohort	90	61 to 90 days	9.209	10% (-10% to 26%)
		BNT162b2	Cohort	150	91 to 150 days	9.133	-77% (-95% to -60%)
		mRNA-1273	Cohort	30	1 to 30 days	37.321	37% (-70% to 76%)
		mRNA-1273	Cohort	60	31 to 60 days	27.219	30% (-41% to 65%)
		mRNA-1273	Cohort	90	61 to 90 days	15.459	4% (-31% to 30%)
		mRNA-1273	Cohort	150	91 to 150 days	10.612	-39% (-62% to -20%)
Šmíd et al., 2022**	Positive	Mixture	Cohort	60	0 to 2 months	0.510	43% (42% to 44%)
	Covid-19	Mixture	Cohort	120	2+ months	0.510	9% (8% to 10%)
	Severe	Mixture	Cohort	60	0 to 2 months	7.143	45% (29% to 57%)
	Infection	Mixture	Cohort	120	2+ months	4.082	29% (21% to 37%)

*Data of full dose in Accorsi et al., 2022 calculated from crude data of number of infected individuals

**Smid et al., 2022 reports two full dose datasets, the one that exclude previous infection and with previous infection. We included the data that exclude previous infection for the analysis

*Studies whose data of Days Latitude are only day 7 or below and NR are excluded from the meta-regression analysis.

S.4. Summary of outcomes for booster dose

Table S5. Summary of outcomes for booster dose

Authors	Endpoints	Vaccine	Design	Days Latitude	Follow-up Interval	SE of VE	VE (95%CI)
Accorsi et al., 2022	Symptomatic	BNT162b2	Case-control	30	7+ days	1.531	65% (62% to 68%)
	Infection	mRNA-1273	Case-control	30	7+ days	1.276	72% (69% to 74%)
Andrews et al., 2022	Symptomatic	BNT162b2	Case-control	7	1 week	0.383	67% (66% to 68%)
	Infection	BNT162b2	Case-control	35	2 to 4 weeks	0.332	67% (67% to 68%)
		BNT162b2	Case-control	70	5 to 9 weeks	0.408	55% (54% to 56%)
		BNT162b2	Case-control	105	10+ week	5.867	46% (45% to 68%)
		ChAdOx1 nCov-19	Case-control	7	1 week	8.597	58% (38% to 71%)
		ChAdOx1 nCov-19	Case-control	35	2 to 4 weeks	5.230	56% (44% to 65%)
		ChAdOx1 nCov-19	Case-control	70	5 to 9 weeks	5.714	47% (34% to 57%)
		mRNA-1273	Case-control	7	1 week	1.301	64% (62% to 67%)
		mRNA-1273	Case-control	35	2 to 4 weeks	1.276	65% (62% to 67%)
Buchan et al., 2021	Severe infection	Mixture of mRNA	Case-control	6	0 to 6 days	6.633	91% (71% to 97%)
		Mixture of mRNA	Case-control	14	7+ days	2.806	95% (87% to 98%)
	Symptomatic	Mixture of mRNA	Case-control	6	0 to 6 days	3.571	36% (29% to 43%)
	Infection	Mixture of mRNA	Case-control	14	7+ days	2.296	61% (56% to 65%)
Chemaitelly et al.,	Symptomatic	BNT162b2	Case-control	7	1 week	7.015	16% (1% to 28%)
2022	Infection	BNT162b2	Case-control	21	2 to 3 weeks	6.097	53% (41% to 65%)
		BNT162b2	Case-control	42	4 to 5 weeks	2.781	57% (51% to 62%)
		BNT162b2	Case-control	63	6 to 7 weeks	3.138	46% (40% to 52%)
		BNT162b2	Case-control	84	8 to 9 weeks	4.694	38% (28% to 47%)
		BNT162b2	Case-control	105	10 to 11 weeks	5.051	44% (33% to 53%)
		BNT162b2	Case-control	126	12+ weeks	4.235	38% (29% to 45%)
		mRNA-1273	Case-control	7	1 week	15.332	4% (-31% to 29%)

		mRNA-1273	Case-control	21	2 to 3 weeks	5.638	53% (41% to 63%)
		mRNA-1273	Case-control	42	4 to 5 weeks	6.097	55% (41% to 65%)
		mRNA-1273	Case-control	63	6+ weeks	8.597	39% (19% to 53%)
Ferdinand et al., 2022	Symptomatic	Mixture of mRNA	Case-control	60	0 to 2 months	0.765	87% (85% to 88%)
	Infection	Mixture of mRNA	Case-control	180	2 to 3 months	0.765	81% (79% to 82%)
		Mixture of mRNA	Case-control	240	3 to 4 months	3.061	66% (59% to 71%)
		Mixture of mRNA	Case-control	300	5+ months	30.102	31% (-50% to 68%)
	Severe	Mixture of mRNA	Case-control	60	0 to 2 months	1.276	91% (88% to 93%)
	infection	Mixture of mRNA	Case-control	180	2 to 3 months	1.276	88% (85% to 90%)
		Mixture of mRNA	Case-control	240	4+ months	4.592	78% (67% to 85%)
Gray et al., 2021	Positive Covid-19	Ad26.COV2	Case-control	14	0 to 13 days	3.567	32% (25% to 39%)
		Ad26.COV2	Case-control	28	14 to 27 days	3.674	14% (7% to 22%)
		Ad26.COV2	Case-control	87	27 to 28 days	6.857	6% (-6% to 20%)
	Severe	Ad26.COV2	Case-control	13	0 to 13 days	13.265	93% (47% to 99%)
	Infection	Ad26.COV2	Case-control	27	14 to 27 days	11.224	81% (49% to 93%)
Klein et al., 2022	Symptomatic Infection (Age 5-11 years)	BNT162b2	Case-control	67	14 to 67 days	8.929	51% (30% to 65%)
	Symptomatic	BNT162b2	Case-control	149	14 to 149 days	6.888	45% (30% to 57%)
	Infection (Age 12-15 years)	BNT162b2	Case-control	299	150+ days	10.714	-2% (-25% to 17%)
	Symptomatic infection	BNT162b2	Case-control	149	14 to 149 days	11.480	34% (8% to 53%)
	(Age 16-17 years)	BNT162b2	Case-control	299	150+ days	12.245	-3% (-30% to 18%)
Lauring et al., 2022	Severe infection	Mixture of mRNA	Case-control	N/A	7+ days	4.337	86% (75% to 92%)
Monge et al., 2022	Positive Covid-19	Mixture	Case-control	34	7 to 34 days	0.561	51% (50% to 52%)
Natarajan et al., 2022	Symptomatic Infection	Mixture	Case-control	120	7 to 120 days	0.510	83% (82% to 84%)

	Severe infection	Mixture	Case-control	120	7 to 120 days	0.765	90% (88% to 91%)
Tartof et al., 2022	Severe	BNT162b2	Case-control	90	0 to 3 months	2.296	89% (83% to 92%)
	infection	BNT162b2	Case-control	180	3 to 5 months	10.459	90% (57% to 98%)
	Symptomatic	BNT162b2	Case-control	90	6+ months	2.296	78% (73% to 82%)
	Infection	BNT162b2	Case-control	180	270+ days	14.286	48% (13% to 69%)
Tenforde et al., 2022	Severe infection	Mixture of mRNA	Case-control	60	60 days (median)	2.296	94% (88% to 97%)
Thompson et al., 2022	Symptomatic Infection	Mixture of mRNA	Case-control	N/A	14+ days	1.276	82% (79% to 84%)
	Severe infection	Mixture of mRNA	Case-control	N/A	14+ days	3.571	90% (80% to 94%)
Tseng et al., 2022	Severe infection	mRNA-1273	Case-control	N/A	14+ days	6.046	99% (76% to 100%)
	Positive	mRNA-1273	Case-control	60	14 to 60 days	0.944	72% (70% to 74%)
	Covid-19	mRNA-1273	Case-control	120	60+ days	3.342	51% (44% to 57%)
Yong-Xu, 2022	Severe infection	Mixture of mRNA	Case-control	N/A	NR	2.296	91% (85% to 94%)
Hansen et al., 2021	Positive Covid-19	BNT162b2	Cohort	30	1 to 30 days	10.179	55% (31% to 70%)
Šmíd et al., 2022	Symptomatic	Mixture	Cohort	60	60 to 120 days	0.255	56% (55% to 56%)
	Infection	Mixture	Cohort	120	120+ days	1.020	21% (19% to 23%)
	Severe	Mixture	Cohort	60	60 to 120 days	5.357	87% (73% to 94%)
	infection	Mixture	Cohort	120	120+ days	2.041	79% (75% to 83%)

*Studies whose data of Days Latitude are N/A or less than 7 days are excluded from the analysis.

S.5. Summary of outcomes for booster vs full dose of the within 3 months or more model

Table S6. Summary of outcomes for booster vs full dose of the within 3 months or more model

Authors	Outcomes	Design	Vaccine	VED (95%CI)	SE of VED
Abu-Raddad et al., 2022	Symptomatic Infection	Cohort	BNT162b2	50.6% (50.18% to 51.02%)	0.213
Abu-Raddad et al., 2022	Symptomatic Infection	Cohort	mRNA-1273	52.7% (51.53% to 53.87%)	0.597
Abu-Raddad et al., 2022	Severe infection	Cohort	BNT162b2	23.5% (20.57% to 26.43%)	1.497
Accorsi et al., 2022	Symptomatic Infection	Case-control	BNT162b2	64.9% (64.34% to 65.46%)	0.284
Accorsi et al., 2022	Symptomatic Infection	Case-control	mRNA-1273	59.5% (58.81% to 60.19%)	0.352
Andrews et al., 2022	Symptomatic Infection	Cohort	ChAdOx1 nCov-19	27.29% (16.16% to 38.43%)	5.68
Andrews et al., 2022	Symptomatic Infection	Cohort	BNT162b2	28.15% (26.5% to 29.79%)	0.841
Andrews et al., 2022	Symptomatic Infection	Cohort	mRNA-1273	33.96% (28.34% to 39.59%)	2.869
Buchan et al., 2021	Symptomatic Infection	Case-control	mixture of mRNA	35.85% (24.81% to 46.89%)	5.633
Buchan et al., 2021	Severe infection	Case-control	mixture of mRNA	24.21% (-33.37% to 81.79%)	29.377
Chemaitelly et al., 2022	Symptomatic Infection	Case-control	mRNA-1273	6% (-14.52% to 26.51%)	10.466
Chemaitelly et al., 2022	Symptomatic Infection	Case-control	BNT162b2	9.01% (-23.82% to 41.83%)	16.748
Ferdinand et al., 2022	symptomatic Infection	Case-control	mixture of mRNA	22.33% (16.9% to 27.77%)	2.774

DSILIVE COVID-19	Conort	BN116262	78.54% (53.26% to 103.81%)	12.895
mptomatic Infection	Case-control	BNT162b2	41.7% (21.43% to 61.98%)	10.345
evere infection	Case-control	mixture of mRNA	2% (-4.88% to 8.88%)	3.512
mptomatic Infection	Case-control	mixture of mRNA	29% (26.41% to 31.59%)	1.321
evere infection	Case-control	mixture of mRNA	17.5% (14.87% to 20.13%)	1.342
evere infection	Case-control	Mixture	46% (35.35% to 56.65%)	5.436
ositive Covid-19	Case-control	Mixture	1.5% (-3.94% to 6.94%)	2.774
mptomatic Infection	Case-control	BNT162b2	33% (24.98% to 41.02%)	4.09
evere infection	Case-control	BNT162b2	19% (-0.18% to 38.18%)	9.788
evere infection	Case-control	mixture of mRNA	15% (12.88% to 17.12%)	1.082
evere infection	Case-control	mixture of mRNA	9% (-1.9% to 19.9%)	5.563
ositive Covid-19	Case-control	mixture of mRNA	30% (25.07% to 34.93%)	2.516
evere infection	Case-control	mRNA-1273	14.7% (7.49% to 21.91%)	3.676
ositive Covid-19	Case-control	mRNA-1273	27.6% (20.4% to 34.8%)	3.674
ositive Covid-19	Case-control	mixture of mRNA	21% (20.14% to 21.86%)	0.437
	mptomatic Infection vere infection vere infection vere infection vere infection sitive Covid-19 mptomatic Infection vere infection vere infection vere infection sitive Covid-19 vere infection sitive Covid-19 vere infection sitive Covid-19	note controlcontrolmptomatic InfectionCase-controlwere infectionCase-controlwere infectionCase-controlvere infectionCase-controlvere infectionCase-controlsitive Covid-19Case-controlmptomatic InfectionCase-controlvere infectionCase-controlvere infectionCase-controlvere infectionCase-controlvere infectionCase-controlvere infectionCase-controlvere infectionCase-controlvere infectionCase-controlvere infectionCase-controlvere infectionCase-controlsitive Covid-19Case-controlositive Covid-19Case-controlsitive Covid-19Case-controlsitive Covid-19Case-controlsitive Covid-19Case-controlsitive Covid-19Case-control	International DescriptionCase-controlBNT162b2were infectionCase-controlmixture of mRNAmptomatic InfectionCase-controlmixture of mRNAvere infectionCase-controlmixture of mRNAvere infectionCase-controlMixturesitive Covid-19Case-controlMixturemptomatic InfectionCase-controlMixturewere infectionCase-controlBNT162b2vere infectionCase-controlBNT162b2vere infectionCase-controlBNT162b2vere infectionCase-controlmixture of mRNAvere infectionCase-controlmixture of mRNAvere infectionCase-controlmixture of mRNAvere infectionCase-controlmixture of mRNAsitive Covid-19Case-controlmixture of mRNAvere infectionCase-controlmixture of mRNAsitive Covid-19Case-controlmRNA-1273sitive Covid-19Case-controlmRNA-1273sitive Covid-19Case-controlmixture of mRNA	International ControlDefinitionDefinitionmptomatic InfectionCase-controlBNT162b241.7% (21.43% to 61.98%)were infectionCase-controlmixture of mRNA2% (-4.88% to 8.88%)mptomatic InfectionCase-controlmixture of mRNA29% (26.41% to 31.59%)vere infectionCase-controlmixture of mRNA17.5% (14.87% to 20.13%)vere infectionCase-controlMixture46% (35.35% to 56.65%)sitive Covid-19Case-controlMixture1.5% (-3.94% to 6.94%)mptomatic InfectionCase-controlBNT162b233% (24.98% to 41.02%)were infectionCase-controlBNT162b219% (-0.18% to 38.18%)vere infectionCase-controlmixture of mRNA15% (12.88% to 17.12%)vere infectionCase-controlmixture of mRNA9% (-1.9% to 19.9%)vere infectionCase-controlmixture of mRNA30% (25.07% to 34.93%)vere infectionCase-controlmixture of mRNA30% (25.07% to 34.93%)vere infectionCase-controlmRNA-127314.7% (7.49% to 21.91%)sitive Covid-19Case-controlmRNA-127327.6% (20.4% to 34.8%)sitive Covid-19Case-controlmRNA-127321% (20.14% to 21.86%)

S.6. Summary of outcomes for booster vs full dose of the within 3 months model

Table S7. Summary of outcomes for booster vs full dose of the within 3 months model

Authors	Outcomes	Design	Vaccine	VED (95% CI)	SE_diff
Andrews et al., 2022	Symptomatic Infection	Cohort	ChAdOx1 nCov-19	16.11% (2.41 to 29.82%)	6.99
Andrews et al., 2022	Symptomatic Infection	Cohort	BNT162b2	17.64% (16.24 to 19.05%)	0.717
Andrews et al., 2022	Symptomatic Infection	Cohort	mRNA-1273	16.52% (12.45 to 20.59%)	2.075
Buchan et al., 2021	Symptomatic Infection	Case-control	mixture of mRNA	27.25% (-5.06 to 59.56%)	16.485
Chemaitelly et al., 2022	Symptomatic Infection	Case-control	BNT162b2	0% (-6.08 to 6.08%)	3.103
Chemaitelly et al., 2022	Symptomatic Infection	Case-control	mRNA-1273	33% (-21.38 to 87.38%)	27.744
Tartof et al., 2022	Symptomatic Infection	Case-control	BNT162b2	-5.72% (-19.59 to 8.15%)	7.077
Abu-Raddad et al., 2022	Symptomatic Infection	Cohort	BNT162b2	-7.7% (-38.69 to 23.29%)	15.812
Abu-Raddad et al., 2022	Symptomatic Infection	Cohort	mRNA-1273	2% (-8.26 to 12.26%)	5.234
Natarajan et al., 2022	Symptomatic Infection	Case-control	mixture of mRNA	27.6% (19.15 to 36.06%)	4.314
Klein et al., 2022	symptomatic Infection	Case-control	BNT162b2	33% (23.82 to 42.18%)	4.683
Ferdinand et al., 2022	symptomatic Infection	Case-control	mixture of mRNA	19% (-2.97 to 40.97%)	11.207
Buchan et al., 2021	Severe infection	Case-control	mixture of mRNA	-3.1% (-6.29 to 0.09%)	1.625

Lauring et al., 2022	Severe infection	Case-control	mixture of mRNA	-3.5% (-6.45 to -0.55%)	1.507
Tartof et al., 2022	Severe infection	Case-control	BNT162b2	42% (32 to 52%)	5.102
Smid et al., 2022	Severe infection	Case-control	Mixture	3.5% (0.17 to 6.83%)	1.697
Abu-Raddad et al., 2022	Severe infection	Cohort	BNT162b2	50.6% (48.35 to 52.85%)	1.148
Natarajan et al., 2022	Severe infection	Case-control	mixture of mRNA	23.5% (7.7 to 39.3%)	8.061
Tenforde et al., 2022	Severe infection	Case-control	mixture of mRNA	52.7% (46.4 to 59%)	3.214
Hansen et al., 2022	Positive Covid-19	Cohort	BNT162b2	29% (18.95 to 39.05%)	5.127
Tseng et al., 2022	Positive Covid-19	Case-control	mRNA-1273	17.5% (7.26 to 27.74%)	5.225
Monge et al., 2022	Positive Covid-19	Case-control	mRNA-1273	15% (3.58 to 26.42%)	5.828
Monge et al., 2022	Positive Covid-19	Design	BNT162b2	30% (12.93 to 47.07%)	8.71
Smid et al., 2022	Positive Covid-19	Cohort	Mixture	22.33% (16.11 to 28.56%)	3.176

S.8. Detailed Results of VE Estimates and VE Reduction of Full Dose

Table S9. Detailed results of VE estimates and VE reduction of full dose for any infection outcome

Variable	Overall	Report
Variable Results	OverallMixed-Effects Model (k = 93; tau^2 estimator: REML)logLik devianceAIC-434.8900869.7800875.7800883.3125876.0558tau^2 (estimated amount of residual heterogeneity):741.3064 (SE = 118.5740)tau (square root of estimated tau^2 value):27.2269I^2 (residual heterogeneity / unaccounted variability):99.50%H^2 (unaccounted variability / sampling variability):199.94R^2 (amount of heterogeneity accounted for):9.91%Test for Residual Heterogeneity:QE(df = 91) = 7954.7133, p-val < .0001	Report R^2 = 9.91% VE estimate (%): 50.12 (37.78 to 62.46), p:<.0001 VE reduction estimate (% per month): -2.955 (-4.92 to -0.993), p:0.0036 VE (%) = 50.12 - 0.0985 day
	Model Results:	
	estimate se tval df pval ci.lb ci.ub intrcpt 50.1200 6.2132 8.0667 91 <.0001 37.7783 62.4618 ***	
	Days -0.0985 0.0329 -2.9919 91 0.0036 -0.1640 -0.0331	



	Test of heterogeneity:	
	Q d.f. p-value	
	2.53 1 0.1114	
Reg Plot	N/A	
Variable	BNT162b2	
Results	Mixed-Effects Model (k = 38; tau ² estimator: REML)	R^2 = 24.08%
	logLik deviance AIC BIC AICc -171.6450 343.2899 349.2899 354.0405 350.0399 tau^2 (estimated amount of residual heterogeneity): 717.3130 (SE = 183.0239)	VE estimate (%): 54.62 (35.57 to 73.66), p:<.0001 VE reduction estimate (% per month): -4.821 (-7.851 to -1.791), p:0.0027
	tau (square root of estimated tau ² value): 26.7827 I ² (residual heterogeneity / unaccounted variability): 99.45% H ² (unaccounted variability / sampling variability): 181.89 R ² (amount of heterogeneity accounted for): 24.08%	VE (%) = 54.6182 - 0.1607 day
	Test for Residual Heterogeneity: QE(df = 36) = 1269.8612, p-val < .0001	
	Test of Moderators (coefficient 2): F(df1 = 1, df2 = 36) = 10.4159, p-val = 0.0027	
	Model Results:	
	estimate se tval df pval ci.lb ci.ub intrcpt 54.6182 9.3902 5.8165 36 <.0001 35.5739 73.6624 *** Days -0.1607 0.0498 -3.2274 36 0.0027 -0.2617 -0.0597 **	





Results	Mixed-Effects Model (k = 4; tau^2 estimator: REML)	R^2 = 63.29%
	logLik deviance AIC BIC AICc -7.5277 15.0555 21.0555 17.1349 45.0555	VE estimate (%): 69.35 (-1.91 to 140.62), p:0.0526 VE reduction estimate (% per month):
	tau ² (estimated amount of residual heterogeneity): 99.6973 (SE = 115.8024) tau (square root of estimated tau ² value): 9.9849	-12.777 (-34.947 to 9.39), p:0.1313
	I^2 (residual heterogeneity / unaccounted variability): 88.68% H^2 (unaccounted variability / sampling variability): 8.84 R^2 (amount of heterogeneity accounted for): 63.29%	VE (%) = 69.3531 - 0.4259 day
	Test for Residual Heterogeneity: QE(df = 2) = 23.7186, p-val < .0001	
	Test of Moderators (coefficient 2): F(df1 = 1, df2 = 2) = 6.1503, p-val = 0.1313	
	Model Results:	
	estimate se tval df pval ci.lb ci.ub intrcpt 69.3531 16.5628 4.1873 2 0.0526 -1.9107 140.6170 . Days -0.4259 0.1717 -2.4800 2 0.1313 -1.1649 0.3130	

Reg Plot	Aactine Effectiveness	
	0.0- 	
Variable	Mixture of mRNA vaccines	D 40 00/
Results	Mixed-Effects Model (k = 25; tau^2 estimator: REML) logLik deviance AIC BIC AICc -108.0914 216.1827 222.1827 225.5892 223.4459 tau^2 (estimated amount of residual heterogeneity): 613.3061 (SE = 201.1280) tau (square root of estimated tau^2 value): 24.7650 I^2 (residual heterogeneity / unaccounted variability): 97.50% H^2 (unaccounted variability / sampling variability): 40.05 R^2 (amount of heterogeneity accounted for): 0.00% Test for Residual Heterogeneity: QE(df = 23) = 628.4139, p-val < .0001	R^2 = 0% VE estimate (%): 62.47 (36.03 to 88.91), p:<.0001 VE reduction estimate (% per month): -1.536 (-5.142 to 2.067), p:0.3868 VE (%) = 62.4733 - 0.0512 day

	Test o F(df1 :	f Moderato = 1, df2 = 2	rs (coefficier 23) = 0.7783,	nt 2): p-val = 0.3868					
	Model	Results:							
	e intrcpt Days	estimate 62.4733 -0.0512	se tval (12.7813 4. 0.0581 -0.	df pval ci.lb 8879 23 <.0001 8822 23 0.3868	ci.ub 36.0331 88.91 -0.1714 0.068	135 *** 39			
Reg Plot	75 -	8	0	0	° 0	٥			
	ŝ			0	0		0		
	Effectivenes	¢		8	0	0			
	Vaccine E	0	o			0	0		
			0	0					
	0 -				0	0			
			100	200 Time in	days	300			
Variable	mRNA	-1273						_	
Results	Mixed logLil	-Effects Mc k deviance	odel (k = 18; e AIC	tau^2 estimator: F BIC AICc	REML)			R^2 = 42.33% VE estimate (%):	

-71.7588 143.5177 149.5177 151.8354 151.5177	51.8 (29.39 to 74.21), p:0.0002
tau^2 (estimated amount of residual heterogeneity):346.2541 (SE = 140.5909)tau (square root of estimated tau^2 value):18.6079I^2 (residual heterogeneity / unaccounted variability):98.12%H^2 (unaccounted variability / sampling variability):53.13R^2 (amount of heterogeneity accounted for):42.33%	VE reduction estimate (% per month): -5.34 (-8.973 to -1.707), p:0.0067 VE (%) = 51.8048 - 0.178 day
Test for Residual Heterogeneity: QE(df = 16) = 344.1080, p-val < .0001	
Test of Moderators (coefficient 2): F(df1 = 1, df2 = 16) = 9.7084, p-val = 0.0067	
Model Results:	
estimate se tval df pval ci.lb ci.ub intrcpt 51.8048 10.5712 4.9006 16 0.0002 29.3949 74.2146 *** Days -0.1780 0.0571 -3.1158 16 0.0067 -0.2991 -0.0569 **	



Cell is denoted as **green** if meta-regression is performed (i.e., if k > 3). Cell is denoted as **yellow** if the result is calculated from meta-analysis of two reports (k = 2).

Variable	overall	
Results	Mixed-Effects Model (k = 15; tau ² estimator: REML)	R^2 = 0%
		VE estimate (%):
	logLik deviance AIC BIC AICc	68.28 (48.71 to 87.85), p:<.0001
	-54.6842 109.3685 115.3685 117.0633 118.0351	VE reduction estimate (% per month):
		-0.534 (-3.516 to 2.451), p:0.7053
	tau ² (estimated amount of residual heterogeneity): 235.8090 (SE = 108.9539)	
	tau (square root of estimated tau^2 value): 15.3561	VE (%) = 68.28 - 0.0178 day
	I/2 (residual heterogeneity / unaccounted variability): 88.26%	
	PA2 (unaccounted variability / sampling variability): 8.52	
	R^2 (amount of neterogeneity accounted for): 0.00%	
	Test for Residual Heterogeneity:	
	QE(df = 13) = 145.4933, p-val < .0001	
	Test of Moderators (coefficient 2):	
	F(df1 = 1, df2 = 13) = 0.1494, p-val = 0.7053	
	Model Results:	
	estimate se tval df pval ci.lb ci.ub	
	intrcpt 68.2800 9.0585 7.5377 13 <.0001 48.7104 87.8497 ***	
	Days -0.0178 0.0460 -0.3865 13 0.7053 -0.1172 0.0817	

Table S10. Detailed results of VE estimates and VE reduction of full dose for severe infection outcome

Reg Plot	0	
	80- 0 0	
	о .	
	A accin	
	•	
	40 -	
	<u> </u>	
	100 200 300 Time in days	
Variable	Ad26.COV2.S	
Results	VE estimate (%): 67 (52 to 77)	VE estimate (%): 67 (52 to 77)
		VE reduction estimate (% per month): N/A
Reg Plot	N/A	
Variable	BNT162b2	
Results	Mixed-Effects Model (k = 4; tau^2 estimator: REML)	R^2 = 63.4%
		VE estimate (%):
	tau ² (estimated amount of residual heterogeneity): 37.0869 (SE = 110.2998)	89.88 (50.39 to 129.38), p:0.0103
	tau (square root of estimated tau^2 value): 6.0899	VE reduction estimate (% per month):
	I^2 (residual heterogeneity / unaccounted variability): 33.62%	-2.715 (-9.177 to 3.747), p:0.2125
	H^2 (unaccounted variability / sampling variability): 1.51	
	R^2 (amount of heterogeneity accounted for): 63.40%	VE (%) = 89.8824 - 0.0905 day



Variable	mixture	
Results	Number of studies combined: k = 2	I^2 = 73.6%
		VE estimate (%):
	VE 95%-CI t p-value	35.9262 (-64.8036 to 136.6561), p:
	Random effects model 35.9262 [-64.8036; 136.6561] 4.53 0.1383	0.1383
		VE reduction estimate (% per month):
	Quantifying heterogeneity:	N/A
	tau^2 = 94.1599; tau = 9.7036	
	I^2 = 73.6% [0.0%; 94.0%]; H = 1.94 [1.00; 4.10]	
	Test of heterogeneity:	
	Q d.f. p-value	
	3.78 1 0.0518	
Reg Plot	N/A	
Variable	Mixture of MRNA	DA0 00 000/
Results	Mixed-Effects Model (K = 8; tau ² estimator: REML)	$R^{2} = 38.23\%$
	lastik davianas AIC DIC AICa	VE estimate (%):
		83.9 (62.22 to 105.58), p < .0001
	-22.0609 44.1616 50.1616 49.5370 62.1616	2220 ($= 0.61 \pm 0.602$) pc0 1022
	t_{2} tau62 (estimated amount of residual betargeneity): 50 2136 (SE = 53 6006)	-2.229 (-5.061 to 0.603), p.0.1025
	tau (square root of estimated tau 02 value): 7 6950	V/E(%) = 83.8956 = 0.0743 day
	1/2 (residual beterogeneity / unaccounted variability): 66.06%	V = (70) = 03.0930 + 0.0743 day
	H^2 (unaccounted variability / sampling variability): 2.95	
	R^2 (amount of heterogeneity accounted for): 38,23%	
	Test for Residual Heterogeneity:	
	QE(df = 6) = 18.3740, p-val = 0.0054	
	Test of Moderators (coefficient 2):	



Cell is denoted as **green** if meta-regression is performed (i.e., if k > 3). Cell is denoted as **yellow** if the result is calculated from meta-analysis of two report (k = 2). Cell is denoted as **orange** if the result is from a report (k = 1) which stays the same as what has been reported by the original study. Cell is denoted as **red** if the result has not been reported by any studies (k = 0).

Variable	overall	
Results	Mixed-Effects Model (k = 59; tau^2 estimator: REML)	R^2 = 37.44%
		VE estimate (%):
	logLik deviance AIC BIC AICc	58.21 (46.26 to 70.15), p:<.0001
	-255.0308 510.0617 516.0617 522.1908 516.5145	VE reduction estimate (% per month):
		-5.202 (-7.116 to -3.285), p:<.0001
	tau ² (estimated amount of residual heterogeneity): 380.0117 (SE = 77.7305)	
	tau (square root of estimated tau/2 value): 19.4939	VE (%) = 58.2061 - 0.1734 day
	HA2 (uppededucted variability / compliant variability): 99.08%	
	RA2 (amount of beterogeneity accounted for): 37 44%	
	Test for Residual Heterogeneity:	
	QE(df = 57) = 3743.4931, p-val < .0001	
	Test of Moderators (coefficient 2):	
	F(df1 = 1, df2 = 57) = 29.5771, p-val < .0001	
	Madel Deputter	
	Model Results:	
	estimate se tval df pval ci.lb ci.ub	
	intrcpt 58.2061 5.9668 9.7551 57 <.0001 46.2579 70.1543 ***	
	Days -0.1734 0.0319 -5.4385 57 <.0001 -0.2372 -0.1095 ***	

Table S11. Detailed results of VE estimates and VE reduction of full dose for symptomatic infection outcome

Reg Plot	90- •	
	Aactive Effectiveness	
	0	
	100 200 300 Time in days	
Variable	Ad26.COV2.S	
Results	VE estimate (%): 54 (43 to 63)	VE estimate (%): 54 (43 to 63)
		VE reduction estimate (% per month): N/A
Reg Plot	N/A	
Variable	BNT162b2	
Results	Mixed-Effects Model (k = 27; tau ² estimator: REML)	R^2 = 64.37%
		VE estimate (%):
	logLik deviance AIC BIC AICc	58.38 (46.09 to 70.67), p:<.0001
	-102.4504 204.9008 210.9008 214.5574 212.0437	VE reduction estimate (% per month): -5.91 (-7.761 to -4.056), p:<.0001
	tau^2 (estimated amount of residual heterogeneity): 185.0191 (SE = 60.1933)	
	tau (square root of estimated tau ² value): 13.6022	VE (%) = 58.3787 - 0.197 day

I^2 (residual heterogeneity / unaccounted variability): 98.50%	
H ² (unaccounted variability / sampling variability): 66.78	
R ² (amount of heterogeneity accounted for): 64.37%	
Test for Residual Heterogeneity:	
QE(df = 25) = 760.6262, p-val < .0001	
Test of Moderators (coefficient 2): F(df1 = 1, df2 = 25) = 43.1650, p-val < .0001	
Model Results:	
estimate se tval df pval ci.lb ci.ub	
intrcpt 58.3787 5.9674 9.7829 25 <.0001 46.0886 70.6687 ***	
Days -0.1970 0.0300 -6.5700 25 <.0001 -0.2587 -0.1352 ***	




Variable	Mixture of mRNA	
Results	Mixed-Effects Model (k = 15; tau^2 estimator: REML) logLik deviance AIC BIC AICc -63.2346 126.4692 132.4692 134.1641 135.1359 tau^2 (estimated amount of residual heterogeneity): 829.6853 (SE = 371.9081) tau (square root of estimated tau^2 value): 28.8043 l^2 (residual heterogeneity / unaccounted variability): 97.99% H^2 (unaccounted variability / sampling variability): 97.99% H^2 (amount of heterogeneity accounted for): 0.00% Test for Residual Heterogeneity: QE(df = 13) = 477.2669, p-val < .0001 Test of Moderators (coefficient 2): F(df1 = 1, df2 = 13) = 0.4370, p-val = 0.5201 Model Results: estimate se tval df pval ci.lb ci.ub intrcpt 55.6158 19.2264 2.8927 13 0.0126 14.0797 97.1519 * Days -0.0631 0.0954 -0.6611 13 0.5201 -0.2693 0.1431	R^2 = 0% VE estimate (%): 55.62 (14.08 to 97.15), p:0.0126 VE reduction estimate (% per month): -1.893 (-8.079 to 4.293), p:0.5201 VE (%) = 55.6158 - 0.0631 day





Cell is denoted as **green** if meta-regression is performed (i.e., if k > 3). Cell is denoted as **orange** if the result is from a report (k = 1) which stays the same as what has been reported by the original study. Cell is denoted as **red** if the result has not been reported by any studies (k = 0).

S.9. Detailed Results of VE Estimates and VE Reduction of Booster Dose

Table S12. Detailed results of VE estimates and VE reduction of booster dose for any infection outcome

Variable	Overall	Report
Results	Mixed-Effects Model (k = 52; tau^2 estimator: REML)	R^2 = 0% VE estimate (%):
	logLik deviance AIC BIC AICc -230.1926 460.3852 466.3852 472.1213 466.9070	66.04 (55.32 to 76.75), p:<.0001 VE reduction estimate (% per month):
		-2.307 (-5.118 to 0.501), p:0.1051
	tau ² (estimated amount of residual heterogeneity): 542.6083 (SE = 115.2483) tau (square root of estimated tau ² value): 23.2940 I ² (residual heterogeneity / unaccounted variability): 99.86% H ² (unaccounted variability / sampling variability): 710.84 R ² (amount of heterogeneity accounted for): 1.18%	VE (%) = 66.037 - 0.0769 day
	Test for Residual Heterogeneity: QE(df = 50) = 8970.2627, p-val < .0001	
	Test of Moderators (coefficient 2): F(df1 = 1, df2 = 50) = 2.7243, p-val = 0.1051	
	Model Results:	
	estimate se tval df pval ci.lb ci.ub intrcpt 66.0370 5.3345 12.3792 50 <.0001 55.3223 76.7517 *** Days -0.0769 0.0466 -1.6505 50 0.1051 -0.1706 0.0167	

Reg Plot	75- 75- 000 000 000 000 000 000 000 000 000 0	
	Let a constrained by the second secon	
Variable	Ad26.COV2.S	
Results	Mixed-Effects Model (k = 5; tau^2 estimator: REML) logLik deviance AIC BIC AICc -15.0520 30.1039 36.1039 33.3997 60.1039 tau^2 (estimated amount of residual heterogeneity): 1254.1640 (SE = 1086.8963) tau (square root of estimated tau^2 value): 35.4142 l^2 (residual heterogeneity / unaccounted variability): 97.44%	R^2 = 11.79% VE estimate (%): 69.16 (-13.52 to 151.85), p:0.0762 VE reduction estimate (% per month): -22.359 (-78.981 to 34.26), p:0.2978 VE (%) = 69.1648 - 0.7453 day
	H^2 (unaccounted variability / sampling variability):39.13 R^2 (amount of heterogeneity accounted for):11.79%Test for Residual Heterogeneity:2001 $QE(df = 3) = 55.1021$, p-val < .0001	

	Model Results: estimate se tval df pval ci.lb ci.ub intrcpt 69.1648 25.9815 2.6621 3 0.0762 -13.5200 151.8496 . Days -0.7453 0.5931 -1.2568 3 0.2978 -2.6327 1.1420	
Reg Plot	sequence of the second	
Variable	BNT162b2	
Results	Mixed-Effects Model (k = 20; tau^2 estimator: REML) logLik deviance AIC BIC AICc -78.0335 156.0670 162.0670 164.7381 163.7812 tau^2 (estimated amount of residual heterogeneity): 282.9738 (SE = 107.4060) tau (square root of estimated tau^2 value): 16.8218 l^2 (residual heterogeneity / unaccounted variability): 99.63% H^2 (unaccounted variability / sampling variability): 270.53 R^2 (amount of heterogeneity accounted for): 36.53% Test for Residual Heterogeneity:	R^2 = 36.53% VE estimate (%): 69.79 (54.94 to 84.65), p:<.0001 VE reduction estimate (% per month): -5.442 (-8.988 to -1.893), p:0.0047 VE (%) = 69.7933 - 0.1814 day

	QE(df = 18) = 1907.8760, p-val < .0001	
	Test of Moderators (coefficient 2):	
	F(df1 = 1, df2 = 18) = 10.3822, p-val = 0.0047	
	Model Results:	
	estimate se tval df pval ci.lb ci.ub	
	intrcpt 69.7933 7.0722 9.8687 18 <.0001 54.9352 84.6513 ***	
	Days -0.1814 0.0563 -3.2221 18 0.0047 -0.2996 -0.0631 **	
Reg Plot	۰ ۰	
	°	
	accine *	
	~ 25-	
	0-	
	100 200 300 Time in days	
Variable	ChAdOx1	
Results	Number of studies combined: k = 2	I^2 = 24.2%
		VE estimate (%):
	VE 95%-CI t p-value Random effects model 51 4480 [-4 9677: 107 8637] 11 59 .0.0548	51.4480 (-4.9677 to 107.8637), p:
		VE reduction estimate (% per month):
	Quantifying heterogeneity:	N/A
	tau^2 = 9.6042; tau = 3.0991; l^2 = 24.2%; H = 1.15	

	Test of heterogeneity: Q d.f. p-value 1.32 1 0.2506	
Reg Plot	N/A	
Variable	Mixture	
Results	Mixed-Effects Model (k = 7; tau^2 estimator: REML) logLik deviance AIC BIC AICc -23.6424 47.2849 53.2849 52.1132 77.2849 tau^2 (estimated amount of residual heterogeneity): 744.5094 (SE = 474.1033) tau (square root of estimated tau^2 value): 27.2857 l^2 (residual heterogeneity / unaccounted variability): 99.94% H^2 (unaccounted variability / sampling variability): 1581.11 R^2 (amount of heterogeneity accounted for): 0.00% Test for Residual Heterogeneity: QE(df = 5) = 3493.4528, p-val < .0001 Test of Moderators (coefficient 2): F(df1 = 1, df2 = 5) = 0.0968, p-val = 0.7683 Model Results: estimate se tval df pval ci.lb ci.ub intrcpt 58.2918 28.7750 2.0258 5 0.0986 -15.6768 132.2603 . Days 0.0921 0.2960 0.3111 5 0.7683 -0.6689 0.8531	R^2 = 0% VE estimate (%): 58.29 (-15.68 to 132.26), p:0.0986 VE reduction estimate (% per month): 2.763 (-20.067 to 25.593), p:0.7683 VE (%) = 58.2918 + 0.0921 day

Reg Plot	So To Jon La Construction de la	
Variable	Mixture of mRNA	
Results	Mixed-Effects Model (k = 10; tau^2 estimator: REML)logLik devianceAICBICAICc-32.5356 65.0712 71.0712 71.3095 77.0712 tau^2 (estimated amount of residual heterogeneity):148.4871 (SE = 81.8958)tau (square root of estimated tau^2 value):12.1855I^2 (residual heterogeneity / unaccounted variability):98.22%H^2 (unaccounted variability / sampling variability):56.20R^2 (amount of heterogeneity accounted for):0.00%Test for Residual Heterogeneity:QE(df = 8) = 215.9954, p-val < .0001Test of Moderators (coefficient 2):F(df1 = 1, df2 = 8) = 1.3832, p-val = 0.2734Model Results:Model Results:	R^2 = 0% VE estimate (%): 88.23 (72.01 to 104.46), p:<.0001 VE reduction estimate (% per month): -1.68 (-4.971 to 1.614), p:0.2734 VE (%) = 88.2341 - 0.056 day





Cell is denoted as **green** if meta-regression is performed (i.e., if k > 3).

Variable	overall	
Results	Mixed-Effects Model (k = 12; tau^2 estimator: REML)	R^2 = 38.93%
	logLik deviance AIC BIC AICc	93.96 (88.3 to 99.63), p<.0001
	-30.9074 61.8147 67.8147 68.7225 71.8147	Decrease (% per month): -1.617 (-3.045 to -0.186), p: <.0001
	tau ² (estimated amount of residual heterogeneity): 13.4208 (SE = 9.8845)	VE (%) = 93.9648 - 0.0539 day
	I^2 (residual heterogeneity / unaccounted variability): 75.90%	
	H ² (unaccounted variability / sampling variability): 4.15 R ² (amount of beterogeneity accounted for): 38,93%	
	Test for Residual Heterogeneity: QE(df = 10) = 32.6589, p-val = 0.0003	
	F(df1 = 1, df2 = 10) = 6.3464 , p-val = 0.0304	
	Madel Deputer	
	estimate se tval df pval ci.lb ci.ub	
	Days -0.0539 0.0214 -2.5192 10 0.0304 -0.1015 -0.0062 *	

Table S13. Detailed results of VE estimates and VE reduction of booster dose for severe infection outcome

Reg Plot	see the set of the set	
Variable	Ad26.COV2.S	
Results	Number of studies combined: $k = 2$ VE 95%-CI t p-value Random effects model 86.0069 [10.8212; 161.1926] 14.53 0.0437 Quantifying heterogeneity: tau^2 = 0; tau = 0; I^2 = 0.0%; H = 1.00 Test of heterogeneity: Q d.f. p-value 0.48 1 0.4898	I ^A 2 = 0% VE estimate (%): 86.0069 (10.8212 to 161.1926), p: 0.0437 VE reduction estimate (% per month): N/A
Reg Plot	N/A	
Variable	BNT162b2	
Results	Number of studies combined: $k = 2$	I ² = 0% VE estimate (%):
	VE 95%-CI t p-value	

	Random effects model 89.0460 [86.3850; 91.7069] 425.20 0.0015 Quantifying heterogeneity: $tau^2 = 0$; $tau = 0$; $l^2 = 0.0\%$; $H = 1.00$ Test of heterogeneity: Q d.f. p-value 0.01	89.0460 (86.3850 to 91.7069), p:0.0015 VE reduction estimate (% per month): N/A
Reg Plot	N/A	
Variable	ChAdOx1 nCov-19	
Results	N/A	
Reg Plot	N/A	
Variable	mixture	
Results	Mixed-Effects Model (k = 3; tau^2 estimator: REML)logLik devianceAIC-3.4703 6.9405 12.9405 6.9405 36.9405 12.9405 6.9405 36.9405 tau^2 (estimated amount of residual heterogeneity): 58.1247 (SE = 85.5599)tau (square root of estimated tau^2 value): 7.6240 I^2 (residual heterogeneity / unaccounted variability): 96.07% H^2 (unaccounted variability / sampling variability): 25.47 R^2 (amount of heterogeneity accounted for): 0.00% Test for Residual Heterogeneity: 0.001 Test of Moderators (coefficient 2): $F(df1 = 1, df2 = 1) = 0.0467, p-val = 0.8645$ Model Results:estimatesetotal dfpvalci.lbci.ub	R^2 = 0% VE estimate (%): 89.34 (-157.54 to 336.22), p:0.1363 VE reduction estimate (% per month): -1.17 (-69.903 to 67.566), p:0.8645 VE (%) = 89.3373 - 0.039 day

	intrcpt 89.3373 19.4298 4.5979 1 0.1363 -157.5421 336.2167 Davs -0.0390 0.1803 -0.2160 1 0.8645 -2.3301 2.2522	
Reg Plot	to the second se	
Variable	Mixture of mRNA	
Results	Mixed-Effects Model (k = 5; tau^2 estimator: REML) logLik deviance AIC BIC AICc -7.1849 14.3698 20.3698 17.6656 44.3698 tau^2 (estimated amount of residual heterogeneity): 1.7452 (SE = 5.1685) tau (square root of estimated tau^2 value): 1.3210 I^2 (residual heterogeneity / unaccounted variability): 27.20% H^2 (unaccounted variability / sampling variability): 1.37 R^2 (amount of heterogeneity accounted for): 91.43% Test for Residual Heterogeneity: QE(df = 3) = 4.1131, p-val = 0.2495	R^2 = 91.43% VE estimate (%): 95.26 (89.19 to 101.34), p:<.0001 VE reduction estimate (% per month): -1.434 (-2.895 to 0.027), p:0.0524 VE (%) = 95.2629 - 0.0478 day
	Test of Moderators (coefficient 2): F(df1 = 1, df2 = 3) = 9.7430, p-val = 0.0524	



Cell is denoted as **green** if meta-regression is performed (i.e., if k > 3). Cell is denoted as **yellow** if the result is calculated from meta-analysis of two report (k = 2). Cell is denoted as **orange** if the result is from a report (k = 1) which stays the same as what has been reported by the original study. Cell is denoted as **red** if the result has not been reported by any studies (k = 0).

Variable	overall	
Results	Mixed-Effects Model (k = 32; tau ² estimator: REML)	R^2 = 15.68% VE estimate (%):
	logLik deviance AIC BIC AICc	65.03 (54.59 to 75.48), p:<.0001
	-129.3988 258.7975 264.7975 269.0011 265.7206	VE reduction estimate (% per month):
	tau^2 (estimated amount of residual heterogeneity): 297.8935 (SE = 84.8558)	0.000 (0.402 10 1.221), p.0.0000
	tau (square root of estimated tau^2 value): 17.2596	VE (%) = 65.0327 - 0.1286 day
	H^2 (unaccounted variability / sampling variability): 517.13	
	R^2 (amount of heterogeneity accounted for): 15.68%	
	Test for Residual Heterogeneity:	
	QE(df = 30) = 6592.3798, p-val < .0001	
	Test of Moderators (coefficient 2):	
	F(df1 = 1, df2 = 30) = 8.9309, p-val = 0.0055	
	Model Results:	
	estimate se tval df pval cille cille	
	intropt 65.0327 5.1151 12.7138 30 <.0001 54.5863 75.4791 ***	
	Days -0.1286 0.0430 -2.9885 30 0.0055 -0.2164 -0.0407 **	

Table S14. Detailed results of VE estimates and VE reduction of booster dose for symptomatic infection outcome

Variable Ad26.COV2.S Results N/A Reg Plot N/A Variable BNT162b2 Results Mixed-Effects Model (k = 17; tau^2 estimator: REML) logLik deviance AIC BIC AICc -57.6048 115.2096 121.2096 123.3337 123.3914 tau^2 (estimated amount of residual heterogeneity): 103.7006 (SE = 47) tau (square root of estimated tau^2 value): 10.1834 I/2 (residual beterogeneity / unaccounted variability): 99.13%	\$
Results N/A Reg Plot N/A Variable BNT162b2 Results Mixed-Effects Model (k = 17; tau^2 estimator: REML) logLik deviance AIC BIC AICc -57.6048 115.2096 121.2096 123.3337 123.3914 tau^2 (estimated amount of residual heterogeneity): 103.7006 (SE = 47) tau (square root of estimated tau^2 value): 10.1834 L^2 (residual beterogeneity / unaccounted variability): 99.13%	
Reg Plot N/A Variable BNT162b2 Results Mixed-Effects Model (k = 17; tau^2 estimator: REML) logLik deviance AIC BIC AICc -57.6048 115.2096 121.2096 123.3337 123.3914 tau^2 (estimated amount of residual heterogeneity): 103.7006 (SE = 47) tau (square root of estimated tau^2 value): 10.1834 L^2 (residual beterogeneity / unaccounted variability): 99.13%	
Variable BNT162b2 Results Mixed-Effects Model (k = 17; tau^2 estimator: REML) logLik deviance AIC -57.6048 115.2096 121.2096 123.3337 123.3914 tau^2 (estimated amount of residual heterogeneity): 103.7006 (SE = 47) tau (square root of estimated tau^2 value): 10.1834 L^2 (residual beterogeneity / unaccounted variability): 99.13%	
Results Mixed-Effects Model (k = 17; tau^2 estimator: REML) logLik deviance AIC BIC AICc -57.6048 115.2096 121.2096 123.3337 123.3914 tau^2 (estimated amount of residual heterogeneity): 103.7006 (SE = 47 tau (square root of estimated tau^2 value): 10.1834 L^2 (residual beterogeneity / unaccounted variability): 99.13%	
H^2 (unaccounted variability / sampling variability): 115.43 R^2 (amount of heterogeneity accounted for): 68.20% Test for Residual Heterogeneity:	R^2 = 68.2% VE estimate (%): 68.79 (59.21 to 78.38), p:<.0001 VE reduction estimate (% per mo -6.423 (-8.898 to -3.948), p:<.00

	F(df1 = 1, df2 = 15) = 30.6190 , p-val < .0001	
	Model Results:	
	estimate se tval df pval ci.lb ci.ub intrcpt 68.7937 4.4963 15.3002 15 <.0001 59.2101 78.3773 *** Days -0.2141 0.0387 -5.5334 15 <.0001 -0.2966 -0.1316 ***	
Reg Plot	B0 60 0 0 0 0 0 0 0 0 0 0 0 0 0	
Variable	ChAdOx1 nCov-19	
Results	Number of studies combined: $k = 2$ VE 95%-CI t p-value Random effects model 51.4480 [-4.9677; 107.8637] 11.59 0.0548 Quantifying heterogeneity: tau^2 = 9.6042; tau = 3.0991; I^2 = 24.2%; H = 1.15	I ^A 2 = 24.2% VE estimate (%): 51.4480 (-4.9677to 107.8637), p:0.0548 VE reduction estimate (% per month): N/A

	Test of heterogeneity:	
	Q d.f. p-value	
	1.32 1 0.2506	
Reg Plot	N/A	
Variable	mixture	
Results	Mixed-Effects Model (k = 3; tau^2 estimator: REML) logLik deviance AIC BIC AICc -5.1995 10.3990 16.3990 10.3990 40.3990	R^2 = 0% VE estimate (%): 59.99 (-1121.52 to 1241.51), p:0.6352 VE reduction estimate (% per month): -1.998 (-343.083 to 339.09), p:0.9527
	tau ² (estimated amount of residual heterogeneity): 1921.3492 (SE = 2718.1185) tau (square root of estimated tau ² value): 43.8332 l ² (residual heterogeneity / unaccounted variability): 99.97% H ² (unaccounted variability / sampling variability): 2953.42 R ² (amount of heterogeneity accounted for): 0.00% Test for Residual Heterogeneity: QE(df = 1) = 2953.4221, p-val < .0001	VE (%) = 59.9937 - 0.0666 day
	Test of Moderators (coefficient 2): F(df1 = 1, df2 = 1) = 0.0055, p-val = 0.9527 Model Results:	
	intropt 59.9937 92.9874 0.6452 1 0.6352 -1121.5233 1241.5107 Days -0.0666 0.8948 -0.0744 1 0.9527 -11.4361 11.3030	







Cell is denoted as **green** if meta-regression is performed (i.e., if k > 3). Cell is denoted as **yellow** if the result is calculated from meta-analysis of two report (k = 2). Cell is denoted as **red** if the result has not been reported by any studies (k = 0).

S.10. Detailed Results of Meta-analyses for the 'Within 3 Months' Model

Variable	k	VED (95%CI)	p-value of VED	Tau2	12 (95%CI)	p-value of I2	Chi^2	df	p-value of Egger's test
Any Infection									
The Overall Result	22	22% (15% to 29%)	<0,0001	0.0207	98.3% (97.9% to 98.6%)	<0,0001	1214.69	21	0.203724
Study Design Subgrou	р:								
Cohort	6	35% (14% to 57%)	<0,0001	0.0678	99.6% (99.4% to 99.7%)	<0,0001	1148.18	5	0.245683
Case-control	16	17% (13% to 21%)	<0,0001	0.0041	76.1% (61.4% to 85.3%)	<0,0001	62.88	15	0.811881
Vaccine Subgroup:									
Ad26.COV2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	8	25% (8% to 41%)	<0,0001	0.0485	98.9% (98.5% to 99.1%)	<0,0001	616.65	7	0.856062
ChAdOx1 nCov-19	1	16% (2% to 30%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	2	27% (-1% to 55%)	<0.0001	0.0407	96.9% (91.8% to 98.8%)	<0.0001	32.17	1	N/A
Mixture of mRNA	7	15% (6% to 24%)	<0.0001	0.0105	79.9% (59% to 90.2%)	<0.0001	29.88	6	0.845442
mRNA-1273	4	25% (4% to 47%)	<0,0001	0.0423	96.8% (94.3% to 98.2%)	<0,0001	94.28	3	0.889649
Severe Infection									
The Overall Result	7	20% (8% to 32%)	<0,0001	0.0193	81.1% (61.9% to 90.6%)	<0,0001	31.8	6	0.919516
Study Design Subgroup:									
Cohort	2	34% (16% to 52%)	0.0525	0.0126	73.4% (0% to 94%)	0.0525	3.76	1	N/A
Case-control	5	13% (5% to 20%)	0.2038	0.0024	32.6% (0% to 74.4%)	0.2038	5.94	4	0.477389
Vaccine Subgroup:									
Ad26.COV2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	2	22% (9% to 35%)	0.7444	0	0% (0% to 0%)	0.7444	0.11	1	N/A
ChAdOx1 nCov-19	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	1	42% (32% to 52%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture of mRNA	4	12% (3% to 21%)	0.1372	0.0036	45.7% (0% to 81.9%)	0.1372	5.52	3	0.65151
mRNA-1273	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Table S15. Detailed Results of meta-analyses for within 3 months model

Symptomatic Infection										
The Overall Result	12	22% (11% to 34%)	<0,0001	0.0371	98.5% (98.1% to 98.8%)	<0,0001	747	11	0.989773	
Study Design Subgroup:										
Cohort	2	51% (49% to 53%)	0.5383	0	N/A	0.5383	0.38	1	N/A	
Case-control	10	17% (12% to 22%)	<0,0001	0.0043	81.3% (66.7% to 89.5%)	<0,0001	48.11	9	0.844111	
Vaccine Subgroup:										
Ad26.COV2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
BNT162b2	5	25% (5% to 46%)	0.0001	0.0504	99.4% (99.1% to 99.5%)	0.0001	616.01	4	0.827264	
ChAdOx1 nCov-19	1	16% (2% to 30%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Mixture	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Mixture of mRNA	3	17% (1% to 33%)	<0.0001	0.0177	90.7% (75.6% to 96.5%)	<0.0001	21.51	2	0.842218	
mRNA-1273	3	23% (-7% to 54%)	<0,0001	0.0065	97.9% (96% to 98.9%)	<0,0001	94.24	2	0.928712	

Abbreviation: k, number of analyses; N/A, not available; VED, vaccine effectiveness difference.

S.11. Detailed Results of Meta-analyses for the 'Within 3 Months or More' Model

Table S16. Detailed Results of meta-analyses for within 3 months or more model

Variable	k	VED (95%CI)	p-value of VED	Tau2	12 (95%CI)	p-value of I2	Chi^2	df	p-value of Egger's test	
Any Infection				<u> </u>						
The Overall Result	28	30% (24% to 37%)	<0.0001	0.0362	97.6% (97% to 98%)	<0.0001	1103.33	27	0.583963	
Study Design Subgr	Study Design Subgroup:									
Cohort	6	43% (22% to 64%)	<0.0001	0.0661	99.3% (99% to 99.5%)	<0,0001	765.77	5	0.52177	
Case-control	22	27% (21% to 34%)	<0.0001	0.019	93.8% (92% to 95.3%)	<0.0001	336.14	21	0.827997	
Vaccine Subgroup:			•						•	
Ad26.COV2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
BNT162b2	9	40% (28% to 52%)	<0.0001	0.0271	97.7% (97% to 98.3%)	<0.0001	345.71	8	0.666296	
ChAdOx1 nCov-19	1	27% (14% to 41%)	<0.0001	N/A	N/A	N/A	N/A	N/A	N/A	
Mixture	2	29% (-4% to 62%)	0.0863	0.0542	96.7% (91% to 98.8%)	<0.0001	30.12	1	N/A	
Mixture of mRNA	10	21% (14% to 27%)	<0.0001	0.0067	79% (62% to 88.4%)	<0.0001	42.93	9	0.796208	
mRNA-1273	6	36% (22% to 50%)	<0.0001	0.0241	93.3% (88% to 96.2%)	<0.0001	74.36	5	0.291389	
Severe Infection										
The Overall Result	9	18% (13% to 23%)	<0.0001	0.0043	88.8% (81% to 93.4%)	<0,0001	71.34	8	0.876591	
Study Design Subgro	oup:									
Cohort	2	35% (13% to 57%)	0.0016	0.0202	80% (14% to 95.3%)	0.0255	4.99	1	N/A	
Case-control	7	11% (5% to 17%)	0.0004	0.0014	21.1% (0% to 64.4%)	0.2688	7.6	6	0.305242	
Vaccine Subgroup:										
Ad26.COV2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
BNT162b2	2	22% (9% to 35%)	0.0008	0	0% (0% to 0%)	0.7444	0.11	1	N/A	
ChAdOx1 nCov-19	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Mixture	1	46% (34% to 58%)	<0.0001	N/A	N/A	N/A	N/A	N/A	N/A	
Mixture of mRNA	5	11% (3% to 18%)	0.005	0.0028	41.8% (0% to 78.6%)	0.1425	6.88	4	0.483804	
mRNA-1273	1	15% (-24% to 54%)	0.4578	N/A	N/A	N/A	N/A	N/A	N/A	

Symptomatic Infection									
The Overall Result	14	37% (29% to 46%)	<0.0001	0.0226	97.1% (96% to 97.8%)	<0.0001	451.64	13	0.755126
Study Design Subgroup:									
Cohort	2	51% (49% to 53%)	0	0	0% (0% to 0%)	0.5383	0.38	1	N/A
Case-control	12	34% (25% to 44%)	<0.0001	0.023	95.5% (94% to 96.8%)	<0,0001	243.29	11	0.444867
Vaccine Subgroup:									
Ad26.COV2	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNT162b2	6	40% (26% to 55%)	<0.0001	0.027	98.5% (98% to 98.9%)	<0.0001	329.82	5	0.652238
ChAdOx1 nCov-19	1	27% (14% to 41%)	<0.0001	N/A	N/A	N/A	N/A	N/A	N/A
Mixture	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mixture of mRNA	3	28% (20% to 36%)	<0.0001	0.0031	61.1% (0% to 88.9%)	0.0767	5.14	2	0.183352
mRNA-1273	4	41% (25% to 56%)	<0.0001	0.0226	94.4% (89% to 97.2%)	<0,0001	53.56	3	0.470046

*The Egger's test has p-value <0.05 but cannot be an indication of publication bias due to k<10. Abbreviation: k, number of analyses; N/A, not available; VE, vaccine effectiveness.

S.12. Sensitivity Analyses for the 'Within 3 Months' Model

Figure S1. The result of leave-one-out sensitivity analyses for any infection endpoint in the 'within 3 months' model

Omitting Abu-Raddad et al., 2022.1		$\hat{\theta}_{1} = 0.20 \ 10.14 \ 0.271 \ l^{2} = 98\%$
Omitting Abu-Raddad et al. 2022		$\hat{\theta}_{1} = 0.21 [0.17 \cdot 0.25]; l^{2} = 9.3\%$
Omitting Šmíd et al. 2022 1		A = 0.21 [0.11-0.23], 7 = 33%
Omitting Tartof et al., 2022.1		6. = 0.21 [0.14-0.20], 7 = 38%
Omitting Fanor et al., 2022		0+ = 0.21 [0.15-0.28]; / = 98%
Omitting Natarajan et al., 2022.1		0+ = 0.22 [0.15-0.28]; / [−] = 98%
Omitting Klein et al., 2022		0 _* = 0.22 [0.15-0.28]; / ² = 98%
Omitting Tseng et al., 2022		θ _* = 0.22 [0.15-0.29]; / ² = 98%
Omitting Hansen et al., 2022		θ. = 0.22 [0.15-0.29]; / ² = 98%
Omitting Buchan et al., 2021		Ô₁ = 0.22 [0.15-0.29]; / ² = 98%
Omitting Abu-Raddad et al., 2022.2	.	θ = 0.22 [0.15-0.29]; / ² = 98%
Omitting Ferdinand et al., 2022	<u>i</u>	θ+ = 0.22 [0.15-0.29]; / ² = 98%
Omitting Andrews et al., 2022.1		θ. = 0.22 [0.13-0.31]; / ² = 98%
Omitting Tartof et al., 2022.1	<u>i</u>	$\hat{\theta}_{*} = 0.22 [0.15 - 0.29]; l^{2} = 98\%$
Omitting Natarajan et al., 2022		$\hat{\theta}_{*} = 0.22 [0.15 - 0.29]; l^{2} = 98\%$
Omitting Andrews et al., 2022		θ. = 0.22 [0.15-0.29]; <i>l</i> ² = 98%
Omitting Andrews et al., 2022.2		θ+ = 0.22 [0.15-0.29]; / ² = 98%
Omitting Šmíd et al., 2022	-	θ. = 0.22 [0.14-0.31]; / ² = 97%
Omitting Tenforde et al., 2022		θ. = 0.22 [0.15-0.29]; / ² = 98%
Omitting Chemaitelly et al., 2022.1		$\hat{\theta}_{*} = 0.23 [0.16 - 0.30]; l^{2} = 98\%$
Omitting Lauring et al., 2022		$\hat{\theta}_{*} = 0.23 [0.16 - 0.30]; l^{2} = 98\%$
Omitting Buchan et al., 2021.1		$\hat{\theta}_* = 0.23 [0.16 - 0.30]; l^2 = 98\%$
Omitting Chemaitelly et al., 2022		θ̂∗ = 0.23 [0.16-0.30]; <i>l</i> ² = 98%
	0.2 Effect Size (Random-Effects Mo	0.6 del)

Sorted by Effect Size



Figure S2. The result of leave-one-out sensitivity analyses for severe infection endpoint in the 'within 3 months' model



Figure S3. The result of leave-one-out sensitivity analyses for symptomatic infection endpoint in the 'within 3 months' model

Sorted by Effect Size

S.13. Sensitivity Analyses for the 'Within 3 Months or More' Model

Figure S4. The result of leave-one-out sensitivity analyses for any infection endpoint in the 'within 3 months or more' model

	0.2	Effect Size (Random-	Effects Model)
	0.2	0.4	0.6
Omitting Lauring et al., 2022		- I	$\hat{\theta}_{1} = 0.32 [0.25 - 0.39]; I^{2} = 98\%$
Omitting Šmíd et al., 2022 —		:	$\hat{\theta}_1 = 0.31 [0.25 - 0.38]; l^2 = 96\%$
Omitting Thompson et al., 2022.1		:	$\hat{\theta}_1 = 0.31 [0.24 - 0.38]; l^2 = 98\%$
Omitting Chemaitelly et al., 2022			θ̂₁ = 0.31 [0.24-0.38]; / ² = 98%
Omitting Tenforde et al., 2022			θ̂ ₁ = 0.31 [0.24-0.38]; / ² = 98%
Omitting Natarajan et al., 2022			$\hat{\theta}_{1} = 0.31 [0.24 - 0.38]; I^{2} = 98\%$
Omitting Chemaitelly et al., 2022.1			$\hat{\theta}_{1} = 0.31 [0.24 - 0.38]; I^{2} = 98\%$
Omitting Yong-Xu et al., 2022			$\hat{\theta}_{1} = 0.31 [0.24 - 0.38]; I^{2} = 98\%$
Omitting Tartof et al., 2022			θ̂. = 0.31 [0.24-0.38]; / ² = 98%
Omitting Ferdinand et al., 2022			$\hat{\theta}_{1} = 0.31 [0.24 - 0.38]; I^{2} = 98\%$
Omitting Tseng et al., 2022		1	$\hat{\theta}_{1} = 0.31 [0.24 - 0.38]; l^{2} = 98\%$
Omitting Abu-Raddad et al., 2022			$\hat{\theta}_{1} = 0.31 [0.24 - 0.38]; l^{2} = 98\%$
Omitting Andrews et al., 2022			$\hat{\theta}_{1} = 0.31 [0.24 - 0.38]; l^{2} = 98\%$
Omitting Tseng et al., 2022.1			$\hat{\theta}_{1} = 0.31 [0.24 - 0.38]; l^{2} = 98\%$
Omitting Buchan et al., 2021			$\hat{\theta}_1 = 0.31 [0.24 - 0.37]; l^2 = 98\%$
Omitting Natarajan et al., 2022.1		-	$\hat{\theta}_{+} = 0.31 [0.23 - 0.38]; I_{-}^{2} = 98\%$
Omitting Thompson et al., 2022			$\hat{\theta}_{1} = 0.30 [0.23 - 0.38]; I^{2} = 98\%$
Omitting Andrews et al., 2022.1			$\hat{\theta}_1 = 0.30 [0.22 - 0.39]; l^2 = 98\%$
Omitting Tartof et al., 2022.1			$\hat{\theta}_{+} = 0.30 [0.23 - 0.37]; I_{-}^{2} = 98\%$
Omitting Andrews et al., 2022.2			$\hat{\theta}_{+} = 0.30 [0.23 - 0.37]; I_{-}^{2} = 98\%$
Omitting Buchan et al., 2021.1			$\hat{\theta}_{+} = 0.30 [0.23 - 0.37]; I_{-}^{2} = 98\%$
Omitting Klein et al., 2022			$\hat{\theta}_{1} = 0.30 [0.23 - 0.37]; t^{2} = 98\%$
Omitting Smíd et al., 2022.1		<u>.</u>	θ. = 0.30 [0.23-0.37]; / ² = 98%
Omitting Abu-Raddad et al., 2022.1			$\hat{\theta}_{1} = 0.30 [0.23 - 0.36]; l^{2} = 96\%$
Omitting Abu-Raddad et al., 2022.2			θ. = 0.30 [0.23-0.37]; / ² = 98%
Omitting Accorsi et al., 2022			0.4 = 0.29 [0.22-0.36]; / ² = 97%
Omitting Hansen et al., 2022			0.29 [0.22-0.36]; / = 98%
			A

Sorted by Effect Size



Figure S5. The result of leave-one-out sensitivity analyses for severe infection endpoint in the 'within 3 months or more' model



Figure S6. The result of leave-one-out sensitivity analyses for symptomatic infection endpoint in the 'within 3 months or more' model Sorted by Effect Size